Pharmaceutical company in Masachussets, United States1
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.3 Its chief executive is Robert Forrester.1 Its shares trade on Nasdaq under the symbol VSTM.1Wikipedia text CC BY-SA 4.0
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Research and developmentSelling, general and admin
Research and development58¢$114.6M
Selling, general and admin41¢$81.1M
Interest1¢$1.1M
Out of $30.9M in revenue.7 The company lost money this year.
Financial statements
Revenue89107$30.9M in 2025+77% since 2019Operating income8911107-$170.1M in 2025+29% since 2019Net income8911107-$209.5M in 2025+40% since 2019
Revenue1213$40.1M in Q2 FY2026+115% since Q1 FY2026Operating income1213-$32.7M in Q2 FY2026−27% since Q1 FY2026Net income1213-$34.7M in Q2 FY2026−5% since Q1 FY2026
Every line of the income statement as filed: the last 3 fiscal years, latest first.7
Period ending
2025-12-31
2024-12-31
2023-12-31
Total revenue
$30.9M
$10.0M
Cost of sales - product
$4.6M
Cost of sales - intangible amortization
$698.0K
Research and development
$114.6M
$81.3M
$61.4M
Selling, general and administrative
$81.1M
$43.6M
$30.7M
Total operating expenses
$201.0M
$125.0M
$92.1M
Loss from operations
-$170.1M
-$115.0M
-$92.1M
Other expense
-$203.0K
-$123.0K
-$109.0K
Interest income
$4.1M
$4.1M
$6.2M
Interest expense
-$1.1M
-$4.6M
-$4.1M
Loss on debt extinguishment
-$1.8M
Change in fair value of preferred stock tranche liability
$4.2M
$2.8M
Change in fair value of warrant liability
-$27.5M
-$19.1M
Change in fair value of Notes
-$12.8M
Net loss before taxes
-$209.5M
-$130.5M
-$87.4M
Income tax expense
-$185.0K
Net loss per share-basic
-$3.02
-$3.66
-$3.96
Net loss per share-diluted
-$3.02
-$3.66
-$3.96
Weighted average common shares outstanding used in computing net loss per share - basic
69.3M shares
35.7M shares
22.1M shares
Weighted average common shares outstanding used in computing net loss per share - diluted
69.3M shares
35.7M shares
22.1M shares
Net loss
-$209.5M
-$130.6M
-$87.4M
Unrealized gain (loss) on available-for-sale securities
-$13.0K
$13.0K
Change in fair value of Notes attributable to instrument specific credit risk
$5.2M
Comprehensive loss
-$204.2M
-$130.7M
-$87.4M
No quarter-by-quarter statement was filed.
Total assets148911107$246.4M in 2025+70% since 2019Total liabilities148911107$189.2M in 2025+37% since 2019Shareholders’ equity911107$57.2M in 2025+697% since 2019Cash148911107$205.0M in 2025+371% since 2019Long-term debt11107$40.7M in 2024+66% since 2022
Total assets1213$206.5M in Q2 FY2026−16% since Q1 FY2025Total liabilities1213$156.5M in Q2 FY2026−17% since Q1 FY2025Shareholders’ equity1213$50.0M in Q2 FY2026−13% since Q1 FY2025Cash1213$136.4M in Q2 FY2026−33% since Q1 FY2025
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.7
Period ending
2025-12-31
2024-12-31
2024-11-30
2023-12-31
2022-12-31
Cash and cash equivalents
$205.0M
$88.8M
Accounts receivable, net
$8.8M
Inventory
$1.8M
Grant receivable
$200.0K
$200.0K
Prepaid expenses and other current assets
$7.6M
$5.9M
Total current assets
$223.4M
$95.0M
Property and equipment, net
$32.0K
Right-of-use asset, net
$491.0K
$1.4M
$1.0M
Restricted cash
$241.0K
Intangible assets, net
$16.4M
Other assets
$6.1M
$4.9M
Total assets
$246.4M
$101.5M
Accounts payable
$12.4M
$4.0M
Accrued expenses, short-term
$54.0M
$26.0M
Vendor financing arrangement, short-term
$5.3M
Lease liability, short-term
$535.0K
$995.0K
Total current liabilities
$72.3M
$31.0M
Long-term debt
$76.3M
$40.7M
Vendor financing arrangement, long-term
$5.0M
Lease liability, long-term
$535.0K
Warrant liability
$35.6M
$58.2M
Total liabilities
$189.2M
$130.4M
Common stock, $0.0001 par value; 300,000 shares authorized, 77,740 and 44,784 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively
$8.0K
$4.0K
Additional paid-in capital
$1.2B
$926.6M
Accumulated other comprehensive income
$5.2M
Accumulated deficit
-$1.2B
-$955.5M
Total stockholders' equity (deficit)
$57.2M
-$28.9M
$57.4M
$47.4M
Total liabilities, convertible preferred stock and stockholders' equity
$246.4M
$101.5M
Preferred stock, shares authorized
5.0M shares
Common stock, par value (in dollars per share)
$0.00
$0.00
Common stock, shares authorized
300.0M shares
300.0M shares
Common stock, shares issued
77.7M shares
44.8M shares
Common stock, shares outstanding
77.7M shares
44.8M shares
Period ending
2025-12-31
2024-12-31
2024-11-30
2023-12-31
2022-12-31
Cash and cash equivalents
$205.0M
$88.8M
Accounts receivable, net
$8.8M
Inventory
$1.8M
Grant receivable
$200.0K
$200.0K
Prepaid expenses and other current assets
$7.6M
$5.9M
Total current assets
$223.4M
$95.0M
Property and equipment, net
$32.0K
Right-of-use asset, net
$491.0K
$1.4M
$1.0M
Restricted cash
$241.0K
Intangible assets, net
$16.4M
Other assets
$6.1M
$4.9M
Total assets
$246.4M
$101.5M
Accounts payable
$12.4M
$4.0M
Accrued expenses, short-term
$54.0M
$26.0M
Vendor financing arrangement, short-term
$5.3M
Lease liability, short-term
$535.0K
$995.0K
Total current liabilities
$72.3M
$31.0M
Long-term debt
$76.3M
$40.7M
Vendor financing arrangement, long-term
$5.0M
Lease liability, long-term
$535.0K
Warrant liability
$35.6M
$58.2M
Total liabilities
$189.2M
$130.4M
Common stock, $0.0001 par value; 300,000 shares authorized, 77,740 and 44,784 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively
$8.0K
$4.0K
Additional paid-in capital
$1.2B
$926.6M
Accumulated other comprehensive income
$5.2M
Accumulated deficit
-$1.2B
-$955.5M
Total stockholders' equity (deficit)
$57.2M
-$28.9M
$57.4M
$47.4M
Total liabilities, convertible preferred stock and stockholders' equity
$246.4M
$101.5M
Preferred stock, shares authorized
5.0M shares
Common stock, par value (in dollars per share)
$0.00
$0.00
Common stock, shares authorized
300.0M shares
300.0M shares
Common stock, shares issued
77.7M shares
44.8M shares
Common stock, shares outstanding
77.7M shares
44.8M shares
Cash from operations8911107-$137.5M in 2025−1% since 2019Capital spending89117$28.0K in 2024+300% since 2019Free cash flow89117-$104.8M in 2024−24% since 2019
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.7
Period ending
2025-12-31
2024-12-31
2023-12-31
Net loss
-$209.5M
-$130.6M
-$87.4M
Depreciation
$30.0K
$26.0K
$62.0K
Amortization of acquired intangible assets
$698.0K
Non-cash operating lease cost
-$81.0K
-$175.0K
-$175.0K
Stock-based compensation expense
$9.4M
$7.3M
$5.9M
Amortization of deferred financing costs, debt discounts and premiums and discounts on available-for-sale marketable securities
$29.0K
-$5.0K
-$1.1M
Change in fair value of preferred stock tranche liability
-$4.2M
-$2.8M
Change in fair value of warrant liability
$27.5M
$19.1M
Non-cash change in fair value of Notes
$6.6M
Loss on debt extinguishment
$1.8M
Accounts receivable, net
-$8.8M
$31.0K
Grant receivable
-$200.0K
Inventory
-$1.8M
Prepaid expenses, other current assets and other assets
-$2.6M
-$596.0K
-$5.8M
Accounts payable
$8.4M
-$3.2M
$2.3M
Accrued expenses and other liabilities
$30.8M
$8.0M
$2.9M
Deferred liabilities
-$327.0K
-$383.0K
Net cash used in operating activities
-$137.5M
-$104.8M
-$86.5M
Purchases of property and equipment
-$28.0K
Purchases of intangible assets
-$9.6M
Purchases of investments
-$96.4M
Maturities of investments
$60.0M
$52.0M
Net cash (used in) provided by investing activities
-$9.6M
$60.0M
-$44.4M
Proceeds from the issuance of common stock and pre-funded warrants, net
$197.0M
$14.2M
$91.4M
Proceeds from the issuance of warrants
$39.6M
Proceeds from issuance of Series B Convertible Preferred Stock, net
$28.1M
Proceeds from exercise of warrants
$33.8M
$875.0K
Proceeds from long-term debt
$75.0M
$14.9M
Repayment of long-term debt
-$42.6M
Payments for loan amendment
-$150.0K
Repayment of 2018 Notes
-$300.0K
Proceeds from insurance premium financing
$1.2M
$1.3M
$1.4M
Payments on insurance premium financing
-$1.2M
-$1.3M
-$1.4M
Proceeds from the exercise of stock options and employee stock purchase program
$116.0K
$241.0K
$57.0K
Net cash provided by financing activities
$263.3M
$54.8M
$134.2M
Increase in cash, cash equivalents and restricted cash
$116.2M
$10.0M
$3.3M
Cash paid for interest
$6.4M
$3.8M
$3.4M
Cash paid for income tax expense
$185.0K
Issuance of preferred stock tranche liability
$6.9M
Purchases of property and equipment included in accounts payable and accrued expenses
$7.0K
Issuance costs included in accounts payable and accrued expenses
$32.0K
Conversion of Series B Convertible Preferred Stock to common stock
$21.2M
Conversion of warrant liability into additional paid-in capital upon warrant exercise
$50.0M
$545.0K
Right of use asset obtained in exchange for operating lease liability
$988.0K
Purchases of intangible asset in accounts payable and accrued expenses
Verastem Oncology sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Verastem Oncology
ARMISTICE CAPITAL, LLCFiled SCHEDULE 13G/A on Verastem Oncology, latest Aug 14, 2026 (3 filings since Feb 17, 2026)
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Verastem Oncology reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
We occupy approximately 27,810 square feet of office space in Needham, Massachusetts under a lease that expires in June 2026. We believe that our facility is sufficient to meet our current needs and that suitable additional space will be available as and when needed.
Verastem Oncology (Verastem Inc) was co-founded in 2010 by entrepreneur Christoph H. Westphal and venture capitalist Michelle Dipp, who provided seed funding and initial office space in Cambridge, MA. The company was formed to commercialize the work of the three other co-founders, MIT biologists Robert Weinberg, Eric S. Lander and Piyush Gupta, by discovering and developing drugs to treat cancer by targeting cancer stem cells.
The company raised $16 million in the initial Series A financing.
Westphal served as CEO and chairman of the board from 2010 to 2013. Under his leadership, the company raised $55 million through an IPO in 2012. Mr. Robert Forrester succeeded Christoph Westphal as Verastem's president and CEO in 2013. In July 2019, Brian Stuglik was appointed to chief executive officer (CEO) of Verastem Oncology.
Mar 28, 2022Reported quarterly or annual results81
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
439 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 66 major events, 196 insider forms, 83 large holders, 74 other. The latest 20:
155 open-market trades by officers, directors and large owners since October 2021: 0 buys and 155 sales. Grants, option exercises and gifts are left out.
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
From the cover page of the 10-K filed Mar 4, 2026 (Section 12(b) of the Exchange Act).16
Risk factors and legal proceedings
The risks Verastem Oncology names in Item 1A of its 10-K filed Mar 4, 2026: 2 risks under these headings, as written.16
Risks Related to the Development of Our Product Candidates and Commercialization of our Product Candidates
Risks Related to Our Commercial Agreements
Risks Related to Our Financial Position and Need for Additional Capital
Risks Related to Our Indebtedness
Risks Related to Our Dependence on Third Parties
Risks Related to Our Intellectual Property
Risks Related to Achieving Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
Risks Related to Employee Matters and Managing Growth
Risks Related to Our Capital Stock
Legal proceedings
From time to time, we are subject to various legal proceedings and claims that arise in the ordinary course of our business activities. We do not believe we are currently party to any pending legal action, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business or operating results.
